New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response

Curr Hematol Malig Rep. 2026 Feb 14;21(1):4. doi: 10.1007/s11899-026-00771-8.ABSTRACTPURPOSE OF REVIEW: Measurable residual disease (MRD) has emerged as the strongest prognostic biomarker in multiple myeloma (MM), providing a deeper assessment of treatment response than conventional serological test

B Bhavesh Mohan Lal

Cardiology's Blind Spot: Mental Health

No abstractEur J Prev Cardiol. 2026 Feb 14:zwag093. doi: 10.1093/eurjpc/zwag093. Online ahead of print.NO ABSTRACTPMID:41689446 | DOI:10.1093/eurjpc/zwag093

F Fabian Sanchis-Gomar